Loading
A phase 2 trial of RO7198457 intravenous (IV) in colorectal cancer, run by BioNTech SE, active and no longer recruiting.
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer is a phase 2 interventional study registered as NCT04486378 by BioNTech SE, with 327 participants enrolled, started 2021-03-08 and due to reach its primary completion in 2026-11. Interventions recorded: RO7198457 intravenous (IV).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/